Aarti Pharmalabs Limited (NSE:AARTIPHARM)

Market Cap	61.30B -7.8%
Revenue (ttm)	18.01B -12.5%
Net Income	2.14B -14.3%
EPS	23.56 -14.3%
Shares Out	90.66M
PE Ratio	28.70
Forward PE	n/a
Dividend	5.00 (0.72%)
Ex-Dividend Date	Feb 16, 2026

Volume	97,318
Average Volume	202,252
Open	676.15
Previous Close	676.15
Day's Range	669.05 - 699.00
52-Week Range	585.00 - 971.00
Beta	0.11
RSI	53.37
Earnings Date	May 8, 2026

About Aarti Pharmalabs

Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system agent, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medications. It also provides con...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2019
• Employees: 2,162
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: AARTIPHARM

Financial Performance

In fiscal year 2025, Aarti Pharmalabs's revenue was 21.15 billion, an increase of 14.17% compared to the previous year's 18.53 billion. Earnings were 2.72 billion, an increase of 25.59%.